Get the Stockscreener App
22.64
0.44%
-0.10
Oculis Holding Ag stock is traded at $22.64, with a volume of 42,767.
It is down -0.44% in the last 24 hours and up +33.33% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$22.74
Open:
$22.75
24h Volume:
42,767
Relative Volume:
0.61
Market Cap:
$949.63M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-11.34
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+0.89%
1M Performance:
+33.33%
6M Performance:
+93.17%
1Y Performance:
+107.52%
1-Day Range:
$22.60
$22.94
1-Week Range:
$21.80
$22.94
52-Week Range:
$10.55
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
22.64 | 949.63M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Oculis Announces Significant Voting Rights Changes Following Íslandsbanki Activity - StockTitan
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care (NASDAQ:OCS) - Seeking Alpha
Oculis Announces Major Voting Rights Changes Involving Íslandsbanki in Switzerland - StockTitan
(OCS) Proactive Strategies - Stock Traders Daily
Oculis (NASDAQ:OCS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Here's What Could Help Oculis Holding AG (OCS) Maintain Its Recent Price Strength - MSN
Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy - MENAFN.COM
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Chardan Capital Reiterates Buy Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's Why - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis' (OCS) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Oculis reiterates shares target, buy rating post-trial - Investing.com
Stifel maintains Oculis stock Buy rating, $35 target post-study - Investing.com India
Oculis Trial Shows Potential for Optical Neuroprotective Therapy - Yahoo Finance
Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis - TipRanks
Stifel maintains Oculis stock Buy rating, $35 target post-study By Investing.com - Investing.com South Africa
Oculis' (OCS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Oculis presents 'groundbreaking' data in optic neuritis with OCS-05 - BioWorld Online
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential... - Markets Insider
OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy - The Manila Times
Oculis' OCS-05 Shows Breakthrough 43% Vision Improvement in Phase 2 Optic Neuritis Trial - StockTitan
Oculis Phase 2 Trial Shows 43% Vision Improvement in Optic Neuritis Treatment Breakthrough - StockTitan
Oculis Publishes Notification of Major Changes in Voting Rights - 24matins.uk
Oculis Holding Announces Major Voting Rights Restructure as Key Shareholder Redistributes Stakes - StockTitan
Oculis Holding (OCS): A Biopharma Opportunity for Adventurous Investors - TipRanks
(OCS) Investment Analysis and Advice - Stock Traders Daily
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Here’s Why - Defense World
Oculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
(OCS) Investment Report - Stock Traders Daily
Oculis Directors Complete RSU Vesting Transaction in Strategic Stock Move - StockTitan
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - MarketBeat
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - Marketscreener.com
Oculis Announces Major Share Vesting Event for Key Executives | OCS Stock News - StockTitan
Where are the Opportunities in (OCS) - Stock Traders Daily
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities - Marketscreener.com
Oculis Awards Equity Incentive to Director Arshad Khanani for Consulting Services | OCS Stock News - StockTitan
Oculis (NASDAQ:OCS) Shares Up 3.8%Here's Why - MarketBeat
(OCS) Investment Analysis - Stock Traders Daily
Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey
Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Reports Q3 2024 Financial Progress - TipRanks
Oculis Holding’s Financial Struggles Amid Asset Growth - TipRanks
Oculis Holding AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):